ARROWHEAD PHARMACEUTICALS, INC. 8-K

What Happened
Arrowhead Pharmaceuticals (ARWR) announced and commented on its fiscal 2026 financial results for the period ended March 31, 2026. The company filed a Form 8-K on May 7, 2026 furnishing a press release with those results (Exhibit 99.1). The filing states the furnished information is not being “filed” for purposes of Section 18 of the Exchange Act and is not incorporated by reference in other filings except as expressly stated.

Key Details

• Filing date: May 7, 2026.
• Reporting period: fiscal 2026 results for the period ended March 31, 2026.
• Press release furnished as Exhibit 99.1; cover page interactive data available as Exhibit 104 (Inline XBRL).
• Per the Form 8-K, the furnished material is not subject to Section 18 liability and is not automatically incorporated by reference into other filings.

Why It Matters
This 8-K signals Arrowhead has released its latest quarterly/period financial results and commentary — important for investors tracking earnings, revenue, cash position, and program updates. Investors should review the attached press release (Exhibit 99.1) for the specific numbers, guidance, or pipeline developments that could affect valuation or near-term trading. Note the company designated the release as “furnished,” which affects its legal status under the Exchange Act.